Early Temferon Trial Shows Engineered Macrophages Reprogram Glioblastoma Niche to Rescue CAR-T Cells

Phase 1/2a testing confirmed safe tumor-targeted interferon-α delivery with clear evidence of microenvironment reprogramming.